CBD shows promise for alcohol use disorder in early trial

NCT ID NCT05159830

Terminated Disease control Sponsor: Hôpital le Vinatier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether cannabidiol (CBD), a non-psychoactive compound from cannabis, could help people with alcohol use disorder reduce their drinking. The study also looked at whether CBD could protect the brain and liver from alcohol's harmful effects. Only 10 people were enrolled before the study was terminated, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) oral oil
What this could lead to: If it works, this could point toward a new treatment option to help people with alcohol use disorder drink less and reduce alcohol-related liver and brain damage.
What could go wrong: This was a very small, early-phase trial that was terminated, so results are limited. CBD may not reduce drinking in humans as it did in mice, and side effects or lack of effect are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

Centre Hospitalier Le Vinatier

Bron, Auvergne-Rhône-Alpes, 69678 cedex, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.